Company Solutions

At-home technologies for monitoring maternal well-being are available and established in clinical practice. For the remote evaluation of fetal well-being, the available technologies are much more limited. Pulsenmore’s ES ultrasound system offers the ability to produce high-quality images that enable the remote evaluation of fetal heartrate, fetal movement, fetal position, amniotic fluid level and position of the placenta. The device docks with the user’s mobile phone and enables her to scan herself at home using a video-guided tutorial, securely upload the encrypted video for review by a qualified healthcare practitioner and receive professional guidance on appropriate next steps.

The device also features a synchronous teleconsultation mode where the healthcare practitioner and the expectant mother can communicate in real time. The expectant mother can share the live image with the healthcare practitioner and receive guidance while performing the scan. Owing to the unique design of the device connected, at-home antenatal ultrasound is now a realistic option at a price point that can be broadly adopted by healthcare systems. The Pulsenmore ES ultrasound system has the potential to revolutionize the delivery and personalization of prenatal care.

When using the device, pregnant women become engaged partners who can perform scans on their unborn babies at their leisure and comfort to meet women where they are. PulseNmore means having access to reliable ultrasound anytime, anywhere—giving reassurance and peace-of-mind to the baby’s parents. For the healthcare practitioner, it means fewer unnecessary emergency room visits, increased productivity and reduced exposure to COVID-19 or other potential sources of infection.

A clinical study assessing women’s ability to successfully perform at home ultrasound was carried out at Rabin Hospital with the results presented at the 2020 ISUOG 30th World Congress on Ultrasound in Obstetrics and Gynecology. In addition, the company is planning or initiating key clinical and health economic studies at prestigious medical centers around the world. Other studies are underway, including the use of our device in a COVID-19 pregnancy ward allowing staff to provide remote state of the art care from a protected location.

The Pulsenmore ES ultrasound system has received the CE Mark for use in the homecare setting. It is currently under FDA review for U.S. marketing authorization. Pulsenmore is in the early stages of market roll-out in Israel and Europe, with market entry planning ongoing for the United States. Pulsenmore signed a significant multi-year purchase agreement with Clalit Health Services, Israel’s leading HMO for the supply of 20,000 devices worth approximately $6M.

Looking For

We are seeking partners who want to incorporate state of the art fetal monitoring into their practice.